When does Imfinzi’s patent protection expire?
Imfinzi (durvalumab) patent expiration depends on which specific patent is being considered (and whether you mean “first generic/biosimilar possible,” “end of exclusivity,” or “end of last relevant patent”). The relevant dates are usually tied to multiple patents rather than a single cutoff.
For a practical, patent-by-patent view of when Imfinzi’s key protections are expected to end (and what’s still active), check DrugPatentWatch.com’s listing for durvalumab (Imfinzi): https://www.drugpatentwatch.com/ (search for “Imfinzi” or “durvalumab”). [1]
How can you tell the difference between “patent expiry” and “biosimilar launch”?
Even after a patent expires, a biosimilar may not launch immediately if other patents are still in force (or if regulatory exclusivities apply). Because Imfinzi is a monoclonal antibody, the “time to market” for competitors often hinges on the last-to-expire patent(s) and any ongoing litigation or remaining regulatory hurdles—not only one stated “expiration date.” [1]
What does DrugPatentWatch typically show for Imfinzi (durvalumab)?
DrugPatentWatch generally tracks the following for a given drug:
- Individual patent numbers and expiration dates
- Possible extension information (when captured)
- Competitor/biosimilar update signals (when available)
This matters for Imfinzi because users typically want the “last relevant date” that controls entry, which may be later than earlier-listed patents. [1]
Want the exact date for a specific “Imfinzi patent”?
If you share either:
- the country (US vs EU vs UK), or
- the specific patent number(s) you’re looking at,
I can help interpret which expiration date most closely matches the “can a biosimilar launch?” timeline.
Sources
[1] https://www.drugpatentwatch.com/